The H1 period at Basilea was notable for another strong performance from the anti-fungal Cresemba (isavuconazole). Underlying growth was reflected in royalty income growth of 21.7% with other revenue of CHF 13.5m boosted by BARDA payments primarily related to fosmanogepix. Based on the H1 performance, and with expectations for continued strong delivery, the company has increased revenue guidance for FY’25 to CHF 225m from CHF 220m, leaving guidance for Cresemba and Zevtera-related revenues unchanged at CHF 190m. Basilea ended H1 2025 with cash and equivalents of CHF 132.7m.
